UNSPSC 51372501: Metheptazine

This classification denotes an opioid receptor agonist with the molecular formula C16H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 93X4R66P5A, chemically known as methyl 1,2-dimethyl-4-phenyl-4-azepanylcarboxylat but generally known as metheptazine, which bears US NIH Compound Identifier 3047717. European Medicines Agency schedules Metheptazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08846MIG. The term METHEPTAZINE is an International Non-Proprietary Name.

UNSPSC 51372501 Metheptazine is a Commodity code nominally for a specific opioid medication, but recent state and local solicitations tagged under this code do not reflect procurement of metheptazine itself. Instead, the code appears in notices for broader pharmaceutical procurement — naloxone (a opioid antagonist), generic multi-source pharmaceuticals and over-the-counter products, and pharmacy benefit program services. State and local health agencies, cooperative purchasing alliances, and health and human services commissions are the primary issuing bodies. The actual work being solicited includes supply agreements for naloxone and drug deactivation systems, cooperative purchasing contracts for generic pharmaceuticals distributed through authorized wholesalers, and market-intelligence requests regarding direct-to-manufacturer prescription programs. Vendors must typically comply with Drug Supply Chain Security Act requirements, Good Manufacturing Practices certification, FDA approval, and proof of legal authorization to work in the United States. Insurance requirements (workers' compensation, general liability, professional liability, network security and privacy coverage) are standard across multi-year pharmaceutical supply agreements.

Recent activity spans Florida, Minnesota (with participation from Oregon through cooperative purchasing), and Texas. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products with evaluation weighted heavily toward price competitiveness at seventy-five percent and requiring vendor relationships with authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson. Seminole County, Florida issued an IFB (posted June 30, 2026, response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the procurement included FEMA funding with associated federal compliance requirements. The Texas Health and Human Services Commission posted a Request for Information on April 3, 2026 to solicit vendor capabilities regarding direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization arrangements. The code shows limited, scattered recent activity and the mismatch between the nominal commodity (metheptazine) and the pharmaceutical categories actually being procured suggests possible classification inconsistency in source databases.